Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.

Journal of clinical pharmacy and therapeutics - 1 Jun 2021

Burns Hailey, Russell Landon, Cox Zachary L

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: Unlike other macrolide antibiotics, azithromycin is considered safe to co-prescribe with simvastatin. We aim to elucidate the mechanism of a rare azithromycin-simvastatin interaction. CASE DESCRIPTION: We report a case of simvastatin-induced rhabdomyolysis caused by an azithromycin drug interaction in a patient with heterozygous SLCO1B1 loss-of-function polymorphism. We propose a...

Topics

Join the communities discussing this publication.

Anti-Bacterial Agents
Azithromycin
Cytochrome P-450 CYP3A Inhibitors
Drug Interactions
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Hypolipidemic Agents

Liver-Specific Organic Anion Transporter 1

Source

Identifiers

PMID: 33277702
DOI: 10.1111/jcpt.13327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.PMID 33277702Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.Semantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Semantic proximity Read ↗

Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.Semantic proximity Read ↗

Statin myotoxicity: a review of genetic susceptibility factors.Semantic proximity Read ↗

Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.Semantic proximity Read ↗

[Genetic marker of statin-induced rhabdomyolysis].Semantic proximity Read ↗

Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report.Semantic proximity Read ↗

Statin-associated myopathy: from genetic predisposition to clinical management.Semantic proximity Read ↗

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Semantic proximity Read ↗

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle ComponentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.